The Institute for Experimental Molecular Imaging (ExMI) at the University Hospital Aachen and the Helmholtz Institute for Biomedical Engineering at RWTH Aachen University is headed by Univ.-Prof. Dr. med. Fabian Kiessling. ExMI focuses on the development of novel contrast agents, imaging techniques and therapeutic approaches to characterize and treat cancer, cardiovascular and inflammatory disorders.

ExMI currently consists of two departments and five research groups:


  • On June 5th, the Uniklinik Aachen founded the Comprehensive Diagnostic Center Aachen (CDCA), which aims to develop, test and establish in collaboration between institutes and clinics of Uniklinik RWTH Aachen and other faculties of RWTH Aachen University tools to automatically evaluate and merge the very different diagnostic data and to employ them efficiently for the benefit of the patient. More information can be found at Comprehensive Diagnostic Center Aachen.
  • Nicolas Groß-Weege was awarded for the best oral presentation at the PSMR conference in Elba in 2018.
  • New microscopic ultrasound technology and clinical application paper published by Opacic et al. in Nature Communications.
  • The Research Training Group “tumor-targeted drug delivery” (2(TD)) coordinated by Fabian Kiessling and Twan Lammers has been granted by the DFG.
  • A second ERC proof-of-concept grant (PIcelles) has been awarded to Twan Lammers.
  • The Center for Biohybrid Medical Systems (CBMS) has been officially opened.